{"id":"W4401668701","doi":"10.1007/s13555-024-01238-5","title":"Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Bausch Health; Sanofi Genzyme; Incyte; CTI Biopharma; Les Laboratories Pierre Fabre; Celldex Therapeutics; Valeant Pharmaceuticals International; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Medac; AbbVie; Baxalta; Celgene; Biogen; Gilead Sciences; Sanofi; Amgen; Pfizer; Galderma; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Discontinuation; Psoriatic arthritis; Psoriasis; Adverse effect; Population; Internal medicine; Dermatology; Surgery","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001089162,0.0001286599,0.001023953,0.000143457,0.00003401902,0.000006584704,0.00002868823,0.0000791895,0.0001234584],"category_scores_gemma":[0.00003526025,0.00008162886,0.0001776669,0.0002504053,0.0001424433,0.00003092226,0.00001482748,0.000106677,0.00000422426],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001040608,"about_ca_system_score_gemma":0.00003553864,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003726565,"about_ca_topic_score_gemma":0.00004355502,"domain_scores_codex":[0.9986737,0.0003000513,0.0005422372,0.000254671,0.0001054398,0.0001239207],"domain_scores_gemma":[0.9989201,0.0006944101,0.00009620774,0.0001706534,0.0000416493,0.00007690739],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006058187,0.0004111221,0.9559278,0.0000342751,0.005544918,0.0004051656,0.000168006,4.765297e-7,7.246425e-7,0.00007627814,0.00002733764,0.03134573],"study_design_scores_gemma":[0.01370922,0.0002432839,0.9840744,0.0001312753,0.001296582,0.00000573031,0.00002072243,0.00004677207,0.000007707836,0.0001417696,0.0002536575,0.00006894824],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9631674,0.03574639,0.00004808264,0.0003449878,0.0001318934,0.0004087562,0.0001134572,0.0000168988,0.00002210183],"genre_scores_gemma":[0.9910119,0.008459037,0.00004805627,0.0001700761,0.00002577219,0.00001987357,0.0002501901,0.000008728453,0.000006336476],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03127678,"threshold_uncertainty_score":0.3328728,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04121194750481737,"score_gpt":0.3684384994092988,"score_spread":0.3272265519044814,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}